2024 REVISIONS TO THE MCDONALD CRITERIA: IMPLICATIONS FOR EARLY AND ACCURATE MULTIPLE SCLEROSIS DIAGNOSIS

Objectives
Recent updates to the diagnostic framework for the initial diagnosis of multiple sclerosis (MS), published in 2024, introduce
key innovations designed to enhance early recognition and diagnostic accuracy. This summary outlines the main changes,
including the integration of specific MRI-based features and adjusted criteria for lesion distribution. These revisions aim to
assist clinicians in applying a more precise and timely diagnostic approach, especially for patients undergoing their first
evaluation with suspected MS. The objective of this analysis is to present an overview of the 2024 modifications to the MS
diagnostic criteria and examine their potential to improve patient assessment and care pathways. The updated protocol
places greater emphasis on imaging and laboratory evidence, aiming to reduce diagnostic uncertainty, particularly in
atypical cases or early disease stages. The goal is to provide healthcare professionals with actionable insights that can be
applied in diverse clinical settings.
Materials and Methods
A structured literature review was conducted to examine the 2024 updates to the MS diagnostic framework. Notably, the
criteria now formally incorporate advanced MRI markers—such as the central vein sign and paramagnetic rim lesions—as
supportive indicators for distinguishing MS from its mimics. The definition of lesion dissemination has been broadened to
include the optic nerve as a valid anatomical site. The diagnostic role of cerebrospinal fluid (CSF) analysis, particularly the
presence of oligoclonal bands (OCBs), remains a cornerstone when imaging findings are inconclusive. Special attention
was given to the implications of these changes for patients with radiologically isolated syndromes (RIS). Additionally, the
review included special considerations for older patients, individuals with vascular comorbidities, and those with
progressive-onset MS, where the application of adapted criteria may reduce diagnostic uncertainty and support earlier
intervention.
Results
The 2024 diagnostic revisions represent a substantial advancement in the identification and classification of multiple
sclerosis. Among the key updates are the options to replace dissemination in time with two alternative findings—such as
positive cerebrospinal fluid (CSF) biomarkers—and to replace dissemination in space with specific imaging-based features,
including ≥6 lesions with a central vein sign or the presence of paramagnetic rim lesions. The expanded imaging criteria
enhance diagnostic specificity, while the inclusion of the optic nerve as a recognized site for lesion dissemination allows for
a more comprehensive assessment of demyelinating activity. These modifications facilitate earlier and more confident
diagnosis, enabling timely treatment initiation that may positively impact long-term disease outcomes. Furthermore, the
updated framework improves the ability to distinguish MS from other inflammatory or structural disorders of the central
nervous system, particularly in complex or atypical cases.
Conclusions
Adopting the revised criteria in clinical practice is expected to lead to more accurate and timely diagnoses, enabling
interventions at an earlier stage of disease progression. As understanding of MS pathology deepens, ongoing refinement of
diagnostic tools—including biomarker validation and imaging advancements—will remain essential to delivering
personalized and effective care.